Pharmaceutical Economics

Pharmaceutical economics studies how societies invent, price, pay for, and distribute medicines.

9 frameworks, from 1970 to today · Health Economics · Economics

still a working view ended · each leads to its entry below

Overview

Pharmaceutical economics studies how societies invent, price, pay for, and distribute medicines1. Its central tension is easy to state and hard to resolve: a new drug costs a great deal to discover and develop but almost nothing to copy, so a market that rewards innovation tends to produce high prices, while a market that drives prices down to the cost of copying tends to stop producing new drugs. Around that tension sit the peculiar institutions of medicine—patents, insurance, formularies, regulators, and the doctor who chooses what the patient receives but does not pay for it. The field's history is the story of building tools to measure value, model competition, and design payment systems that try to hold innovation and access together.

Patents, Monopoly, and the Industrial Organization of Drug Supply

Pharmaceutical economics began as a branch of industrial organization—the study of how firms compete, set prices, and enter and exit markets. The defining feature of the industry is the patent, a temporary legal monopoly granted in exchange for public disclosure of an invention2. In the United States, the modern patent term of twenty years from filing was set by the 1994 Uruguay Round Agreements Act, implementing the TRIPS agreement; before that, patents ran seventeen years from grant. Because a drug must pass years of clinical trials before approval, much of the patent life is consumed before a product reaches the market, a problem economists call the "patent cliff" or effective patent life.

The classic analysis of this trade-off is the 1986 paper by Henry Grabowski and John Vernon, which estimated that the effective patent life of new chemical entities had fallen to roughly half the nominal term, and that imitation by generic firms would erode sales quickly after expiry. Their work framed the central empirical question of the field: how much of the return to innovation is actually capturable, and how fast does competition arrive?

The industry's structure—a few large firms, high fixed costs, and a long, uncertain development pipeline—invited study of research and development as an investment under uncertainty. Grabowski and Vernon's later work, and the broader literature on the "product life cycle," described how a drug's sales rise, peak, and fall as patents expire and generics enter. The 1984 Hatch-Waxman Act in the United States, formally the Drug Price Competition and Patent Term Restoration Act, created the modern generic entry pathway: an abbreviated approval process for generics, plus patent-term extensions and market exclusivity for innovators. It is the institutional hinge on which much of the subsequent literature turns.

The Cost-of-Innovation Debate

How much does it cost to bring a new drug to market? The question matters because it sets the benchmark against which prices and profits are judged. The landmark estimate came from Joseph DiMasi, Ronald Hansen, and Henry Grabowski in 2003: about $802 million per approved new drug, in year-2000 dollars, including the cost of failures and the cost of capital. A 2016 update by DiMasi, Grabowski, and Hansen put the figure at roughly $2.6 billion in 2013 dollars. These numbers became the reference point for industry and for critics alike.

Critics challenged the method. The estimates rely on confidential firm data and on assumptions about the cost of capital and the failure rate. In 2019, Olivier Wouters, Martin McKee, and Jeroen Luyten published a reanalysis arguing that the published figures were not reproducible and that the true cost was likely lower. The debate is unresolved and is itself a feature of the field: the cost of innovation is not a fact you can look up but a quantity you must model, and the model's assumptions drive the answer.

Economic Evaluation: Measuring Value

If drugs cost money, they must be worth it. The tool for judging worth is economic evaluation, and its workhorse is cost-effectiveness analysis. The idea is to compare the extra cost of a treatment with the extra health it produces, expressed as an incremental cost-effectiveness ratio, or ICER—the difference in cost divided by the difference in health effect between two options3.

The standard measure of health effect is the quality-adjusted life year, or QALY: a year of life weighted by health-related quality of life, so that a year in perfect health counts as 1 and a year in severe illness counts as less4. The QALY was developed in the 1970s and 1980s; the 1993 book by Michael Drummond and colleagues, Methods for the Economic Evaluation of Health Care Programmes, became the standard methods text. The approach spread through national agencies—Australia's Pharmaceutical Benefits Advisory Committee began requiring cost-effectiveness evidence for reimbursement in the early 1990s, and the UK's National Institute for Health and Care Excellence (NICE), founded in 1999, made the ICER central to its decisions, with a threshold range commonly cited around £20,000–£30,000 per QALY.

Cost-effectiveness analysis has a rival in cost-benefit analysis, which values health in money terms, and a complement in cost-utility analysis, which uses preference-weighted health states. The field's methodological arguments—whose preferences count, how to weight future benefits, whether to use a societal or health-system perspective—are not settled, and they recur whenever a new agency adopts the method.

Insurance Design and Demand-Side Cost-Sharing

A third strand concerns the demand side: how patients and insurers respond to prices. The RAND Health Insurance Experiment, conducted between 1974 and 1982, randomly assigned families to insurance plans with different levels of cost-sharing and found that higher cost-sharing reduced spending, largely by reducing the number of visits and prescriptions rather than their intensity. The finding established that patients respond to prices, which raised the question of whether they respond well—that is, whether they cut valuable care along with wasteful care.

The answer came from the "value-based insurance design" literature, which argued that cost-sharing should be low for high-value services and high for low-value ones5. The idea was articulated by Mark Fendrick and colleagues in the early 2000s and has been adopted in various benefit designs. The broader lesson—that insurance changes behavior, and that the design of the cost-sharing schedule is itself a policy lever—links pharmaceutical economics to the economics of moral hazard and adverse selection.

Generic Competition and the Product Life Cycle

The generic entry literature is where industrial organization and policy meet most directly. After Hatch-Waxman, generic firms could challenge patents and enter with bioequivalent copies. Empirical work documented the "generic erosion" of innovator sales: within months of expiry, generic prices fall sharply and the innovator's market share collapses. The 1990s and 2000s saw a wave of "authorized generics" and patent settlements, and economists studied whether these arrangements delayed entry.

The product life cycle model—sales rising with adoption, peaking, then falling at patent expiry—became the standard frame for forecasting and for valuing a drug pipeline. It also underpins the policy debate over "evergreening," the practice of extending exclusivity through minor reformulations or new indications, which critics argue delays the price competition that generics bring.

Health Technology Assessment and Reimbursement Gatekeeping

As costs rose, payers built institutions to decide what to cover. Health technology assessment, or HTA, is the systematic evaluation of a technology's clinical and economic value as a basis for reimbursement. NICE in the UK is the most studied example; Germany's Institute for Quality and Efficiency in Health Care (IQWiG), founded in 2004, and Canada's CADTH play similar roles. The gatekeeping function is the point: an HTA body can refuse to pay for a drug whose ICER exceeds its threshold, which gives the agency bargaining power over price.

The economics of HTA is the economics of a monopsonist—a single buyer facing many sellers—and the literature has studied how thresholds, confidential discounts, and risk-sharing agreements affect launch prices and innovation. The UK's 2014 introduction of "managed access" agreements, under which drugs are funded while further evidence is collected, is one institutional response to the uncertainty that HTA exposes.

Global Pricing and Access

Drug prices vary enormously across countries, and the field studies why. The standard explanation is Ramsey pricing: charging more in markets with less elastic demand and less in poor countries, subject to the constraint that parallel trade and reference pricing limit how far price discrimination can go. The 2001 anthrax scare and the HIV/AIDS treatment crisis in Africa brought global access to the center of the field; the Doha Declaration on TRIPS and Public Health (2001) affirmed that countries could issue compulsory licenses for public-health reasons.

The empirical literature on global pricing—including work on external reference pricing, under which one country's price is set by reference to others—shows that price regulation in one market spills over into others. The COVID-19 pandemic sharpened the debate, with advance purchase agreements and tiered pricing for vaccines becoming a live case study in global access policy.

Causal Inference and the Credibility Revolution

A methodological transformation swept the field from the 1990s onward: the "credibility revolution," in which economists sought research designs that mimic randomization. In pharmaceutical economics, this meant using natural experiments—patent expirations, formulary changes, regulatory thresholds—to identify causal effects. The 1990s work of Joshua Angrist and Guido Imbens on instrumental variables and the broader literature on difference-in-differences and regression discontinuity gave the field tools to answer questions that had previously been descriptive.

A concrete example: studying the effect of a drug's patent expiry on prices and utilization requires separating the expiry from other trends, and difference-in-differences designs using unaffected drugs as controls became standard. The approach is now the default in empirical pharmaceutical economics, and it has been applied to questions from the effect of direct-to-consumer advertising to the impact of prior authorization on medication adherence.

Value-Based and Outcomes-Based Pricing

The newest strand tries to tie price to measured value. Value-based pricing sets a drug's price according to its health benefit, often using the ICER; outcomes-based or performance-based agreements make payment conditional on real-world results, with rebates if a drug underperforms. The idea is to share the risk of uncertain effectiveness between payer and manufacturer. Early examples include outcomes-based contracts for multiple sclerosis drugs and, more recently, gene therapies with installment payment models. The economics is that of a principal-agent problem under uncertainty: the payer cannot observe the drug's true value until it is used, so the contract must be designed to elicit truthful reporting and efficient use.

The Present

Pharmaceutical economics today is a mature applied field with four working cores: empirical industrial organization, which models competition and entry; economic evaluation, which measures value; insurance and payment design, which shapes demand; and causal-inference econometrics, which supplies the identification strategies. The open questions are the old ones in new form—how to reward innovation without denying access, how to price drugs whose value is uncertain, how to coordinate prices across countries without starving research, and how to measure the cost of innovation in a way that survives scrutiny. The field's history is a record of building institutions and methods to hold those questions open rather than to settle them once and for all.

References

  1. Pharmacoeconomics, Wikipedia
  2. Patent, Wikipedia
  3. Health economics (Health utility), Wikipedia
  4. Quality-adjusted life year, Wikipedia
  5. Value-based insurance design, Wikipedia

The frameworks of Pharmaceutical Economics

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1970-Present

    Industrial Organization of Pharmaceuticals

    How do patents and firm structure shape drug prices?

    Fly to its tower in Nousfarer

  2. 1975-Present

    Insurance Design and Demand-Side Cost-Sharing

    How does cost-sharing change patients' use of care?

    Fly to its tower in Nousfarer

  3. 1980-Present

    Economic Evaluation

    How do we measure whether a treatment is worth its cost?

    Fly to its tower in Nousfarer

  4. 1984-Present

    Generic Competition and the Product Life Cycle

    How fast do generics take over after patent expiry?

    Fly to its tower in Nousfarer

  5. 1990-Present

    Cost-of-Innovation Modeling

    How much does it cost to bring a new drug to market?

    Fly to its tower in Nousfarer

  6. 1990-Present

    Health technology assessment

    Who decides which treatments get paid for?

    Fly to its tower in Nousfarer

  7. 1995-Present
  8. 1995-Present

    Global Pricing and Access

    Why do drug prices differ so much across countries?

    Fly to its tower in Nousfarer

  9. 2005-Present

    Value-Based and Outcomes-Based Pricing

    Should a drug's price depend on how well it works?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Industrial Organization of Pharmaceut…Insurance Design and Demand-Side Cost…Economic EvaluationGeneric Competition and the Product L…Cost-of-Innovation ModelingHealth technology assessmentCausal Inference and the Credibility …Global Pricing and AccessValue-Based and Outcomes-Based Pricing

Beyond the field

Where Pharmaceutical Economics's ideas came from in other fields, and what they led to there: the strongest 12 of 32 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Pharmaceutical Economics is a planet in Nousfarer

Its city has a tower for each of these 9 frameworks. Land, walk in, and climb one concept at a time.

Land on Pharmaceutical Economics

Related fields

Fields its ideas are linked to

More in Health Economics

See where Pharmaceutical Economics sits on the Map of Human Knowledge